Anti-CD51 (Victronectin receptor ) [NKIM7] monoclonal antibody
Invented at Netherlands Cancer Institute
- References (1)
- Inventor Info
|Applications||FACS IHC IP|
|Antigen/Gene or Protein Targets||CD51|
|Synonyms||ITGAV; Integrin Subunit Alpha V|
|Relevance||ITGAV encodes integrin alpha chain V. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain. Alpha V undergoes post-translational cleavage to yield disulfide-linked heavy and light chains, that combine with multiple integrin beta chains to form different integrins. Among the known associating beta chains (beta chains 1,3,5,6, and 8; 'ITGB1', 'ITGB3', 'ITGB5', 'ITGB6', and 'ITGB8'), each can interact with extracellular matrix ligands; the alpha V beta 3 integrin, perhaps the most studied of these, is referred to as the Vitronectin receptor (VNR). In addition to adhesion, many integrins are known to facilitate signal transduction|
|Immunogen||Cultured melanoma cells derived from a human melanoma metastasis.|
|Molecular Weight (kDa)||116|
|Recommended Growing Conditions||RPMI +10% FBS ultra low IgG, 37 ⁰C 5% CO2|
Fusion partners: SP2/0 x spleen cells origin BALB/C.
The antibody reacts strongly with melanoma cells derived from cell lines and short term cultures and melanoma cells in frozen tissue sections.
|Research Area||Adhesion, Cell Structure and Motility, Immunology|
There are 1 reference entries for this reagent.View All References
No inventors are currently linked to this reagent.
Add an inventor
Add an inventor